Evidence map›Paper›PMID 25253356›Full record

ArticleJournal of virology2014

Type I interferon signaling enhances CD8+ T cell effector function and differentiation during murine gammaherpesvirus 68 infection.

Ryan N Jennings, Jason M Grayson, Erik S Barton

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. CD8Viruses · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. STAT1 maintains naïve CD8Science advances · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Influence ofFrontiers in immunology · 2021
    Review
  16. Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  17. ΔJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryan N JenningsDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Jason M GraysonDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Erik S BartonDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA ebarton@wakehealth.edu.
Wake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Laboratory Animal & Comparative Medicine TrainingT32OD010957 · OD · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI J. MARK CLINE · 2012 to 2026
$4.3M
Interferon Alpha Regulation of Murine Gammaherpesvirus LatencyR01AI080775 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GRAYSON, JASON MITCHELL · 2010 to 2014
$1.8M
Redox control of CD8 T cell proliferation, differentiation and deathR01AI068952 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GRAYSON, JASON MITCHELL · 2008 to 2012
$1.6M
Function and regulation of SirT1 in cancerR01CA121291 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI CHEN, JIANDONG · 2007 to 2011
$1.4M
NCI NIH HHS P30 CA012197NCI NIH HHS P30 CA121291-37NCI NIH HHS R01 CA121291NIAID NIH HHS R01 AI068952NIAID NIH HHS R01-AI068952NIAID NIH HHS R01 AI080775NIAID NIH HHS R01-AI080775NIH HHS OD-010957NIH HHS T32 OD010957
6 · The paper itself

Abstract

unlabelledCD8(+) T cell responses are critical to the control of replication and reactivation associated with gammaherpesvirus infection. Type I interferons (IFNs) have been shown to have direct and indirect roles in supporting CD8(+) T cell development and function during viral infection; however, the role of type I interferons during latent viral infection has not been examined. Mice deficient in type I IFN signaling (IFNAR1(-/-) mice) have high levels of reactivation during infection with murine gammaherpesvirus 68 (MHV68), a murine gammaherpesvirus model for Epstein-Barr virus. We hypothesized that type I IFNs function to enhance the anti-gammaherpesvirus CD8(+) T cell response. To test this, IFNAR1(-/-) mice were infected with MHV68 and the CD8(+) T cell response was analyzed. In the absence of type I IFN signaling, there was a marked increase in short-lived effector CD8(+) T cells, and MHV68-specific CD8(+) T cells had upregulated expression of PD-1 and reduced tumor necrosis factor alpha (TNF-α), gamma IFN (IFN-γ), and interleukin-2 (IL-2) production. Suppressing MHV68 replication early in infection using the antiviral cidofovir rescued CD8(+) T cell cytokine production and reduced PD-1 expression. However, suppressing high levels of reactivation in IFNAR1(-/-) mice failed to improve CD8(+) T cell cytokine production during latency. T cell-specific abrogation of type I IFN signaling showed that the effects of type I IFNs on the CD8(+) T cell response during MHV68 infection are independent of direct type I IFN signaling on T cells. Our findings support a model in which type I IFNs likely suppress MHV68 replication, thus limiting viral antigen and facilitating an effective gammaherpesvirus-directed CD8(+) T cell response. IMPORTANCE: The murine gammaherpesvirus MHV68 has both genetic and biologic homology to the human gammaherpesvirus Epstein-Barr virus (EBV), which infects over 90% of humans. Latent EBV infection and reactivation are associated with various life-threatening diseases and malignancies. Host suppression of gammaherpesvirus latency and reactivation requires both CD8(+) T cells as well as type I interferon signaling. Type I IFNs have been shown to critically support the antiviral CD8(+) T cell response in other virus models. Here, we identify an indirect role for type I IFN signaling in enhancing gammaherpesvirus-specific CD8(+) T cell cytokine production. Further, this function of type I IFN signaling can be partially rescued by suppressing viral replication during early MHV68 infection. Our data suggest that type I IFN signaling on non-T cells can enhance CD8(+) T cell function during gammaherpesvirus infection, potentially through suppression of MHV68 replication.

Indexed as

Cell DifferentiationSignal TransductionAnimalsCD8-Positive T-LymphocytesCytokinesHerpesviridae InfectionsInterferon Type IMiceMice, KnockoutProgrammed Cell Death 1 ReceptorRhadinovirusTumor Virus InfectionsCytokinesInterferon Type IPdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Identifiers

PMID25253356
PMCPMC4249115
OpenAlexW2021636143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.